Table 2. Detection of autoantibodies in patients with ON.
| RON (n = 76) | BON (n = 54) | ION (n = 60) | p1 | p2 | p3 | |
| ANA(1∶160) | 7 (9.21%) | 3 (5.56%) | 1 (1.67%) | |||
| ANA(1∶320) | 8 (13.33%) | 6 (11.11%) | 1 (1.67%) | |||
| ANA(1∶640) | 3 (3.95%) | 0 (0.00%) | 1 (1.67%) | |||
| ANA(1∶1000) | 2 (2.62%) | 2 (3.70%) | 0 (0.00%) | |||
| 20 (26.32%) | 11 (20.37%) | 3 (5.00%) | 0.432 | <0.001** | 0.013** | |
| SSA | 18 (22.78%) | 2 (3.70%) | 2 (2.25%) | |||
| SSB | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | |||
| SSA+SSB | 5 (6.58%) | 0 (0.00%) | 1 (1.67%) | |||
| 23 (30.26%) | 2 (3.70%) | 3 (5.00%) | <0.001** | <0.001** | 1.00 | |
| ACL | 2 (2.63%) | 0 (0.00%) | 1 (1.67%) | |||
| β2-GPI | 5 (6.58%) | 5 (9.26%) | 1 (1.67%) | |||
| ACL+β2-GPI | 2 (2.63%) | 1 (1.85%) | 3 (3.37%) | |||
| 9 (11.84%) | 6 (11.11%) | 5 (8.33%) | 0.64 | 0.15 | 0.63 | |
| A-AQP-4 Ab(>1∶10) | 10 (13.16%) | 3 (5.56%) | 0 (0.00%) | 0.044* | 0.01** | 0.103 |
| A-ds DNA | 3 (3.95%) | 1 (1.85%) | 0 (0.00%) | 0.868 | 0.333 | 0.958 |
| RF | 5 (6.58%) | 0 (0.00%) | 0 (0.00%) | 0.144 | 0.117 | N/A |
| Total | 39 (51.31%) | 21 (38.89%) | 8 (13.33%) | 0.16 | <0.001** | 0.002** |
ANA: antinuclear antibody, SSA and SSB: extractable nuclear antigen antibodies, RF:rheumatoid factor,ACL: anticardiolipin antibody, AQP-4: aquaporin-4; A-ds DNA: anti-double-stranded DNA antibody;
* = p<0.05; ** = p<0.01. p1 = RON vs. BON; p2 = RON vs. ION; p3 = BON vs. ION.